RxDoctor Payments Data

Eribeth Penaranda, MD

Family Medicine · El Paso, TXNPI 1548480312

Payments from drug & device makers

$6,038in general payments, 2019–2025

Across 230 payments — averaging $26.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novo Nordisk$918
  • AstraZeneca$763
  • Lilly USA, LLC$728
  • Amgen$451
  • Boston Scientific$348
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$6,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,038 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$189,393
Medicare patients
214
Services billed
3,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$110,952
EliquisApixaban29$46,847
ProliaDenosumab14$24,281
JanuviaSitagliptin Phosphate14$22,876
MounjaroTirzepatide18$18,929
TrulicityDulaglutide11$16,410
FarxigaDapagliflozin Propanediol16$12,741
SynthroidLevothyroxine Sodium26$2,931
Atorvastatin Calcium279$2,443
Levothyroxine Sodium239$2,165
ProgesteroneProgesterone, Micronized42$2,160
Losartan Potassium178$2,105
Nebivolol Hcl11$1,166
Lisinopril149$1,153
Alendronate Sodium112$1,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$918$110,95279 claims
PfizerEliquis$84$46,84729 claims
Lilly USA, LLCMounjaro, Trulicity$728$35,33829 claims
AmgenProlia$451$24,28114 claims
AstraZenecaFarxiga$763$12,74116 claims
AbbVieSynthroid$220$2,93126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →